去甲氧柔红霉素增强预处理的造血干细胞移植治疗骨髓增生异常综合征及其护理  

Idarubicin Enhanced Pretreated Hematopoietic Stem Cell Transplantation in the Treatment of Myelodysplastic Syndrome

作　　者：林静[1] 胡慧[1] 徐玉兰[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院风湿科,武汉420022

出　　处：《成都医学院学报》2014年第5期644-647,共4页Journal of Chengdu Medical College

基　　金：华中科技大学自助创新研究基金项目(NO:2014QN059);医院临床学科重点项目(卫规财函[2013]353号)

摘　　要：目的探讨去甲氧柔红霉素(IDA)增强预处理方案的外周血造血干细胞移植对骨髓增生异常综合征(MDS)的治疗及护理措施。方法对12例MDS患者施以IDA增强预处理的外周血干细胞移植治疗及护理。结果12例患者均植活成功,显示该预处理方案耐受良好,经过精心的护理,8例患者生存,预期3年总存活率(OS)为66.7%,无病生存率(DFS)为58.3%,2例患者复发。结论 IDA增强预处理的外周血造血干细胞移植,同时辅以正确的护理措施对MDS治疗有效,能降低复发率。Objective To study the effect of Idarubicin （IDA） on the pretreated peripheral blood hematopoietic stem cell transplantation in the treatment of myelodysplastic syndrome and nursing measures. Methods 12 patients with myelodysplastic syndrome were administered IDA to enhance pretreated peripheral blood stem cell transplantation and nursing. Results all of the 12 cases were engrafted successfully shown that the pretreatment solution tolerated well. With careful nursing,8 patients survived and it was expected that the overall survival （OS） rate was 66.7% ,the disease-free survival rate was 58.3% and 2 cases of patients had a recurrence. Conclusion IDA do increase peripheral blood hematopoietic stem cell transplantation. Meanwhile, taking the correct nursing measures are effective to the treatment of myelodysplastic syndrome,and cocan reduce the recurrence rate.

关 键 词：去甲氧柔红霉素 异基因外周造血干细胞移植 骨髓增生异常综合征 

分 类 号：R55[医药卫生—血液循环系统疾病] R473[医药卫生—内科学]